Bristol-Myers Squibb Company

NYSE: BMY
$57.13
-$1.37 (-2.3%)
Real Time Data Delayed 15 Min.

BMY Articles

The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) in a close second....
The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks shrank.
These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500 companies.
A series of new reports from Jefferies focus on some of the top stocks in the pharmaceutical and biotech arenas. Almost all these stocks have data that could send shares measurably higher.
The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO). Unfortunately, the move was to the downside.
The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care sector is on the move.
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow they have for the rest of 2017.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly upward.
Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
Here are five good blue chip dividend stocks that are reasonably safe and offer good dividends, and they look good for the slow summer trading and the rest of 2017.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.